Last reviewed · How we verify
fIPV
At a glance
| Generic name | fIPV |
|---|---|
| Sponsor | University of Vermont |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV) (PHASE4)
- Comparison of Immunogenicity of Inactivated Poliovirus Vaccine (IPV) Administered Intramuscularly or Intradermally (PHASE2)
- Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT (PHASE1)
- Immunogenicity of Intramuscular and Intradermal IPV (PHASE4)
- Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administered at 9-13 Months of Age in Bangladesh (PHASE4)
- Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study (PHASE4)
- Use of mOPV1 in Routine Immunization in Pakistan. (NA)
- Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |